The bacteria Mycobacterium tuberculosis is the primary cause of the deadly infectious illness tuberculosis (TB). Antibiotics can treat TB, but the rise of drug-resistant TB strains presents a significant threat to world health. Drug-resistant TB is brought on by TB bacterium strains that are immune to one or more of the common medicines used to treat TB, making treatment more challenging and costly.
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis are the two primary kinds of drug-resistant TB (XDR-TB). According to Dr. Nikhil Modi, Senior Consultant, Respiratory and Critical Care Medicine, Indraprastha Apollo Hospitals, “XDR-TB is resistant to these two drugs as well as several of the second-line drugs used to treat MDR-TB, whereas MDR-TB is resistant to the two most potent first-line drugs, isoniazid and rifampin.
New therapies are urgently required to address the problem of drug-resistant TB. Dr. Modi advises the following strategies that should be used:
Create new medications: Pharmacies may spend money on the investigation and creation of fresh medications with a focus on tackling drug-resistant TB. This might include finding new therapeutic targets, creating novel drug classes, and running clinical studies to evaluate the effectiveness and safety of such medications.
Enhance already-existing medications: Researchers may attempt to enhance currently-existing TB medications to increase their efficacy against drug-resistant strains. This may include creating fresh formulations or delivery systems, such as medication formulations that may be injected or inhaled.
Employ combination treatment to treat TB to help stop the spread of drug-resistant strains. Combination therapy includes treating TB with various medications at once. This strategy may also be utilized to treat drug-resistant TB by combining several medications that focus on certain TB bacterium traits.
Create vaccinations: Although not a cure for drug-resistant TB, immunizations may help stop the disease’s spread and lighten its overall impact. One of the main objectives of global health researchers is the creation of an efficient TB vaccine.
Increased detection and diagnosis is required for successful TB treatment and to stop the development of drug-resistant strains. Early TB detection and diagnosis is thus essential. The development of quick diagnostic tests, for example, may assist to detect drug-resistant bacteria early and allow immediate treatment.
A multifaceted strategy including research, development, and deployment of novel medicines as well as enhanced detection and preventive techniques will be needed to address the problems posed by drug-resistant TB.
